Complementing our metabolic disease expertise, Woodland Biosciences specializes in cancers of the liver and pancreas but also offers a wide range of cell-line based xenografts, including lung, colon, brain and breast cancers.  Over 400 human cell lines in 22 indications are available for both in vitro and in vivo studies.  SBH Sciences is a key partner for in vitro studies and biomarkers.

Services - Oncology: 

Woodland has recently partnered with Repositive (repositive.io) who have a master list of many of the oncology models from around the world. Working with them we will do exome sequencing on several of our most popular models to enable mutation-based analysis of your drug.





Othotopic and Flank Xenografts

>400 human cancer cell lines
in vitro and in vivo studies

Woodland Biosciences has provided standard or custom-designed studies with CDX models to over 30 companies worldwide.

With over 400 cell lines available, call us to see if we have run yours, or to schedule a pilot growth study for your in vivo model needs.

We built our reputation by solving client needs and making it right. We know how to plan a study and customize our offering to specific client needs. We have performed combination drug studies, long-term treatment with recurrence, drug resistance (failure) modeling and PD biomarker fine needle biopsy sampling.  We also have an IVIS 200 imaging system (Perkin Elmer) for in-life, non-invasive imaging of tumor growth in both luminescence and fluorescence modes.

Ask about our work with tumor spheroids and microenvironment (see R&D section for more).

Patient-Derived Xenografts

The ultimate measure of your drug's activity

At Woodland Biosciences, we believe that mouse modeling of human cancers is fraught with challenges and translation to the clinic is not always assured.  We work with leading academic hospitals to develop novel models of human cancers.  Our primary focus is in liver cancer and we have started to collect a representative sampling of the HCC occuring in North America.  Our collection will include patients with HCC derived from HCV, HBV and alcoholic induced liver cancers.  We model in our metabolic disease work, cancers that are arising from obesity and diabetes and NASH / cirrhosis, a new and challenging cause of liver cancer.  While our focus is in liver cancer, we have lung, colon and colon metastases to the liver as well. Our tumor bank is represented on Repositive (repositive.io).